2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

101. Red Cells and Erythropoiesis, Excluding Iron: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality of Care, Diseases, Bone Marrow Failure Syndromes, Genetic Disorders, Hemoglobinopathies, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Other Pathogens, Metabolic Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

4630 Sirolimus as an effective treatment in children with chronic/refractory primary and secondary autoimmune hemolytic anemia

Maurizio Miano, MD, Damiano Lemmi, MD2, Valentina Savino, MD3, Riccardo Morini, MD4, Gianluca Dell'Orso, MD5, Eugenia Mariani, MD6, Luca Arcuri, MD7, Maria Giarratana, MD8, Daniela Guardo9, Erika Massaccesi10, Elena Palmisani11, Francesca Fioredda, MD12, Carlo Dufour I, MD13
1 IRCCS Istituto Giannina Gaslini, Genoa, Italy
2 IRCCS Istituto Giannina Gaslini, Genoa, Italy
3 IRCCS Istituto Giannina Gaslini, Genoa, Italy
4 IRCCS Istituto Giannina Gaslini, Genoa, Italy
5 IRCCS Istituto Giannina Gaslini, Genoa, Italy
6 IRCCS Istituto Giannina Gaslini, Genoa, Italy
7 IRCCS Istituto Giannina Gaslini, Genoa, Italy
8 IRCCS Istituto Giannina Gaslini, Genoa, Italy
9 IRCCS Istituto Giannina Gaslini, Genoa, Italy
10 IRCCS Istituto Giannina Gaslini, Genoa, Italy
11 IRCCS Istituto Giannina Gaslini, Genoa, Italy
12 IRCCS Istituto Giannina Gaslini, Genoa, Italy
13 IRCCS Istituto Giannina Gaslini, Genoa, Italy

Background: Autoimmune hemolytic anemia (AIHA) is a rare disorder that may follow a chronic or refractory course. Therapeutic management beyond first-line steroid treatment remains challenging. Sirolimus has been shown to be useful in AIHA secondary to Autoimmune Lymphoproliferative Syndrome or in the setting of Evans syndrome, but limited data are available on its use in isolated/primary disease.

Aims: To retrospectively evaluate the efficacy and safety of sirolimus in pediatric patients with refractory or steroid-dependent AIHA.

Methods: We conducted a retrospective single-center study including children with chronic or refractory primary AIHA or secondary AIHA treated with sirolimus. Sirolimus was administered as maintenance therapy at a starting dose of 2 mg/m², with further dose adjustments based on blood levels. Treatment response was defined as complete (CR) in the presence of age-adjusted hemoglobin levels normalization and absence of clinical evidence of hemolysis, or partial (PR) in the case of a sustained hemoglobin increase ≥2 g/dL from baseline with reduced transfusion requirements, despite persistent minor hemolysis.

Results: Twenty-three children with a median age of 16,2 years (range 2,8-25,9) suffering from AIHA received sirolimus for refractory or steroid-dependent disease. In six (23%) patients AIHA was also associated with pure red cell aplasia. Thirteen out of these 23 (57%) patients had primary disease. In the remaining 10 (43%) cases AIHA was secondary to Inborn errors of immunity (IEI). In six (23%) patients AIHA was also associated with the autoimmune involvement of other blood cells. Median hemoglobin at diagnosis was 8 g/dL. Twenty patients received corticosteroids alone as first-line therapy. Sirolimus was started after a median of 380 days from disease onset (range 4–5681 days) together with steroid during the acute fase (3) or as second (n=7), third (n=7), fourth (n=4), or further-line therapy (n=2). All patients achieved a response which was complete and partial in 19 (83%) and 3 (13%) of cases, respectively. One patient was lost at follow up. Median time to response was 57 days (range 16–244 days), with a median sirolimus serum levels at response of 8.1 ng/mL (range 4.54–13.67 ng/mL). Eight patients relapsed during treatment (4) or after discontinuation (4), and were successfully managed by dose adjustment or drug reintroduction. No patients discontinued therapy because of adverse events. Median follow-up was 7,0 years (range 0,4–23,9 years).

Conclusions: These findings show that sirolimus is effective not only in children with AIHA secondary to IEI but also in patients with primary disease. The high response rate, durable efficacy, and favorable safety profile suggest that sirolimus may represents an useful option in patients with refractory or steroid-dependent disease. Prospective studies are warranted to further define its role in such a rare condition.

Maurizio Miano, MD: No relevant conflicts of interest to declare.